JP2008513370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513370A5 JP2008513370A5 JP2007531465A JP2007531465A JP2008513370A5 JP 2008513370 A5 JP2008513370 A5 JP 2008513370A5 JP 2007531465 A JP2007531465 A JP 2007531465A JP 2007531465 A JP2007531465 A JP 2007531465A JP 2008513370 A5 JP2008513370 A5 JP 2008513370A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- alkyl
- disorder
- compound
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 44
- 150000001875 compounds Chemical class 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- -1 cyano, nitro, amino Chemical group 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 4
- 230000003287 optical effect Effects 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 claims 3
- FUZYTVDVLBBXDL-UHFFFAOYSA-N 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide Chemical compound N1C2=CC=C(Cl)C=C2C2=C1C(C(=O)N)CCC2 FUZYTVDVLBBXDL-UHFFFAOYSA-N 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102000011990 Sirtuin Human genes 0.000 claims 1
- 108050002485 Sirtuin Proteins 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 230000011759 adipose tissue development Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000000923 atherogenic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
- 0 *C(CCC1)c2c1c(cc(*)cc1)c1[n]2 Chemical compound *C(CCC1)c2c1c(cc(*)cc1)c1[n]2 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/940,269 US20050209300A1 (en) | 2003-09-12 | 2004-09-13 | Methods of treating a disorder |
| US11/077,664 US20060074124A1 (en) | 2003-09-12 | 2005-03-11 | Methods of treating a disorder |
| PCT/US2005/032760 WO2006031894A2 (en) | 2004-09-13 | 2005-09-13 | Methods of treating a disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008513370A JP2008513370A (ja) | 2008-05-01 |
| JP2008513370A5 true JP2008513370A5 (enExample) | 2008-09-18 |
Family
ID=36060677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007531465A Pending JP2008513370A (ja) | 2004-09-13 | 2005-09-13 | 障害を処置する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20060074124A1 (enExample) |
| EP (1) | EP1793817A4 (enExample) |
| JP (1) | JP2008513370A (enExample) |
| AU (1) | AU2005284851A1 (enExample) |
| CA (1) | CA2578355A1 (enExample) |
| MX (1) | MX2007002816A (enExample) |
| WO (1) | WO2006031894A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060074124A1 (en) | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
| WO2007047604A2 (en) * | 2005-10-18 | 2007-04-26 | Elixir Pharmaceuticals, Inc. | Sirt1 inhibition |
| CA2667826C (en) * | 2006-10-28 | 2013-10-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
| WO2008054767A2 (en) * | 2006-10-30 | 2008-05-08 | University Of Southern California | N4 modifications of pyrimidine analogs and uses thereof |
| WO2008060400A2 (en) * | 2006-11-15 | 2008-05-22 | Sirtris Pharmaceuticals, Inc. | Sirtuin polymorphisms and methods of use thereof |
| UA98777C2 (en) * | 2006-11-20 | 2012-06-25 | Эли Лилли Энд Компани | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators |
| EP2102230A2 (en) * | 2006-12-29 | 2009-09-23 | Gloucester Pharmaceuticals, Inc. | Purifiction of romidepsin |
| BRPI0720734A2 (pt) * | 2006-12-29 | 2014-01-07 | Gloucester Pharmaceuticals Inc | Preparação da romidepsina |
| WO2008119070A1 (en) * | 2007-03-28 | 2008-10-02 | Trustees Of Boston University | Methods of treatment using sirt modulators and compositions containing sirt1 modulators |
| WO2009140448A1 (en) * | 2008-05-16 | 2009-11-19 | Eli Lilly And Company | Tetrahydrocyclopenta[b]indole androgen receptor modulators |
| EP2367563A4 (en) | 2008-12-08 | 2012-12-19 | Univ Northwestern | PROCESS FOR HSF-1 MODULATION |
| US8318928B2 (en) * | 2008-12-15 | 2012-11-27 | Glenmark Pharmaceuticals, S.A. | Fused imidazole carboxamides as TRPV3 modulators |
| JP2012076998A (ja) * | 2009-01-29 | 2012-04-19 | Sapporo Medical Univ | メラノーマの転移抑制剤 |
| KR20120034592A (ko) * | 2009-04-09 | 2012-04-12 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｈｉｖ 복제의 저해제 |
| EP3053925A1 (en) | 2010-12-16 | 2016-08-10 | F. Hoffmann-La Roche AG | Tricyclic pi3k inhibitor compounds and methods of use |
| AR088377A1 (es) | 2011-10-20 | 2014-05-28 | Siena Biotech Spa | Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta |
| JP6342910B2 (ja) * | 2012-10-29 | 2018-06-13 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | 遺伝子薬物療法のための新規試薬 |
| WO2016094688A1 (en) | 2014-12-10 | 2016-06-16 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
| KR20170124602A (ko) | 2015-03-13 | 2017-11-10 | 포르마 세라퓨틱스 인크. | Hdac8 억제제로서의 알파-신나미드 화합물 및 조성물 |
| EP3416950A1 (en) | 2016-02-16 | 2018-12-26 | Massachusetts Institute of Technology | Max binders as myc modulators and uses thereof |
| CN110996942A (zh) * | 2017-06-19 | 2020-04-10 | 小利兰.斯坦福大学托管委员会 | 用于降低含有延伸核苷酸重复序列的基因的有害活性的化合物 |
| WO2020083933A1 (en) * | 2018-10-23 | 2020-04-30 | Mexav Biotech Ag | Fusion polypeptides and therapeutic applications thereof |
| AR132691A1 (es) * | 2023-05-16 | 2025-07-23 | Aop Orphan Ip Ag | Preparación de (s)-6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida en forma enantioméricamente enriquecida mediante proceso de resolución |
| CN120118019A (zh) * | 2023-12-08 | 2025-06-10 | 苏州湃芮生物科技有限公司 | 一种RNA m6A调控剂的共晶形式及其制备方法与应用 |
| CN120136769A (zh) * | 2023-12-11 | 2025-06-13 | 苏州湃芮生物科技有限公司 | 一种RNA m6A调控剂的结晶形式及其制备方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3769298A (en) * | 1971-04-02 | 1973-10-30 | Pfizer | Substituted aminomethylcarbazoles |
| BE793493A (fr) * | 1971-12-30 | 1973-06-29 | Hoffmann La Roche | Composes tricycliques |
| DE2226703A1 (de) * | 1972-05-25 | 1973-12-13 | Schering Ag | Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung |
| US4009181A (en) * | 1973-01-22 | 1977-02-22 | Hoffmann-La Roche Inc. | Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof |
| BG25793A3 (bg) * | 1973-07-18 | 1978-12-12 | Schering Aktiengesellschaft | Метод за получаване на карбазолови деривати |
| US4057640A (en) * | 1973-07-18 | 1977-11-08 | Schering Aktiengesellschaft | 5,6,7,8:Tetrahydrocarbazole-1-carboxylic acid derivatives |
| DE2431292A1 (de) | 1974-06-27 | 1976-01-15 | Schering Ag | Neue carbazol-derivate |
| HUT76923A (hu) * | 1994-07-27 | 1998-01-28 | Sankyo Company Limited | Muszkarinreceptorokra alloszterikus hatást kifejtő heterociklusos vegyületek |
| KR20000005175A (ko) * | 1996-04-04 | 2000-01-25 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 테트라하이드로-베타-카르볼린 유도체의 항전이제로서의 용도 |
| US5830911A (en) * | 1996-08-14 | 1998-11-03 | American Home Products Corporation | Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 |
| WO2000002878A1 (en) * | 1998-07-11 | 2000-01-20 | University Of Bristol | Compounds having activity at imidazoline receptors |
| US20010039012A1 (en) * | 1999-06-14 | 2001-11-08 | Lapidus Stanley N. | Methods for diagnostic screening |
| US7241743B2 (en) * | 2001-06-15 | 2007-07-10 | The Trustees Of Columbia University In The City Of New York | Sir2α-based therapeutic and prophylactic methods |
| IL161626A0 (en) * | 2001-12-14 | 2004-09-27 | Zentaris Gmbh | Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr) |
| EP1513522A2 (en) * | 2002-01-18 | 2005-03-16 | Sri International | Methods of treating conditions associated with an edg receptor |
| US7575883B2 (en) * | 2002-12-13 | 2009-08-18 | Elixir Pharmaceuticals, Inc. | Cytochrome c acetylation |
| US20050143371A1 (en) * | 2003-07-23 | 2005-06-30 | Pharmacia Corporation | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
| US20060074124A1 (en) * | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
| CA2538759C (en) * | 2003-09-12 | 2015-11-03 | Elixir Pharmaceuticals, Inc. | Substituted heterocyclic compounds as sirtuin inhitibitors |
| US20050250794A1 (en) * | 2003-12-19 | 2005-11-10 | Andrew Napper | Methods of treating a disorder |
| AU2005208934A1 (en) * | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc | Treating a viral disorder |
-
2005
- 2005-03-11 US US11/077,664 patent/US20060074124A1/en not_active Abandoned
- 2005-09-13 MX MX2007002816A patent/MX2007002816A/es not_active Application Discontinuation
- 2005-09-13 CA CA002578355A patent/CA2578355A1/en not_active Abandoned
- 2005-09-13 JP JP2007531465A patent/JP2008513370A/ja active Pending
- 2005-09-13 EP EP05803803A patent/EP1793817A4/en not_active Withdrawn
- 2005-09-13 AU AU2005284851A patent/AU2005284851A1/en not_active Abandoned
- 2005-09-13 WO PCT/US2005/032760 patent/WO2006031894A2/en not_active Ceased
-
2009
- 2009-04-14 US US12/423,751 patent/US8486990B2/en not_active Expired - Fee Related
-
2013
- 2013-05-24 US US13/902,062 patent/US20140163029A1/en not_active Abandoned
-
2015
- 2015-06-04 US US14/730,398 patent/US20160113903A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513370A5 (enExample) | ||
| JP2007505148A5 (enExample) | ||
| JP2007515429A5 (enExample) | ||
| RU2443691C2 (ru) | Мочевинные активаторы глюкокиназы | |
| JP2004523582A5 (enExample) | ||
| EP2371811A3 (en) | Azetidinecarboxylic acid derivative and medicinal use thereof | |
| JP2009514837A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| JP2010514829A5 (enExample) | ||
| JP2003523996A5 (enExample) | ||
| JP2010526145A5 (enExample) | ||
| JP2011527333A5 (enExample) | ||
| MX2007010532A (es) | Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii. | |
| MY156747A (en) | Isoxazolo-pyridine derivatives | |
| JP2008521829A5 (enExample) | ||
| JP2020502092A5 (enExample) | ||
| JP2010514758A5 (enExample) | ||
| BR112015008717A2 (pt) | composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii | |
| JP2005539045A5 (enExample) | ||
| US7772206B2 (en) | Methods and compositions for the treatment of autoimmune disorders using clofarabine | |
| WO2008088039A1 (ja) | ドネペジルを含有する安定化医薬組成物、その製造方法、及び安定化方法 | |
| RU2014123784A (ru) | Новые производные пирролидина в качестве ингибиторов катепсина | |
| JP2017510645A5 (enExample) | ||
| JP2007519743A5 (enExample) | ||
| JP2017503804A5 (enExample) |